AR013094A1 - N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES - Google Patents
N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINESInfo
- Publication number
- AR013094A1 AR013094A1 ARP980102858A ARP980102858A AR013094A1 AR 013094 A1 AR013094 A1 AR 013094A1 AR P980102858 A ARP980102858 A AR P980102858A AR P980102858 A ARP980102858 A AR P980102858A AR 013094 A1 AR013094 A1 AR 013094A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- compounds
- alkyl
- independently selected
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuestos de urea N-sustituida que comprenden la formula (I) o una sal o solvato farmacéuticamente aceptable del mismo, en donde: A representa N oN-oxido; X representa N, CH o C, de manera que cuando X es N o CH, hay un unico enlace alátomo de carbono 11 segun se representa por la línea solida; ocuando X es C, hay un doble enlace al átomo de carbono 11, segun se representa por las líneas punteada y solida; X1 y X2 son independientemente seleccionadosentre bromo o cloro, y X3 yX4 son independientemente seleccionados, bromo o cloro siempre que por lo menos uno de X3 y X4 sea hidrogeno; Y1 e Y2 sonindependientemente seleccionados entre hidrogeno o alquilo; Z es =O o =S; R5, R6, R7 y R8 cada uno independientementehidrogeno, -C F3, -COR10, alquilo oarilo, y adicionalmente en donde R5 puede combinarse con R6 para representar =O o =S y/o R7 puede combinarse con R8 para representar =O o =S; R10, R19 yR20 representan independientemente hidrogeno, alquilo,alcoxi, arilo,aralq uilo, heteroarilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo,heterocicloalquilo y heterocicloalquilalquilo, con la condicion de que R19 y R20 no sean ambos hidrogeno; v es cero, 1, 2 o 3; y W es cero o1;composiciones farmacéuticas que s on inhibidores de la enzima, transferasa de proteína farnesilo y uso de dichos compuestos para preparar medicamentos utilespara inhibir el crecimiento anormal de células.N-substituted urea compounds comprising formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: A represents N or N-oxide; X represents N, CH or C, so that when X is N or CH, there is a single carbon 11 atom bond as represented by the solid line; When X is C, there is a double bond to carbon atom 11, as represented by the dotted and solid lines; X1 and X2 are independently selected from bromine or chlorine, and X3 and X4 are independently selected from bromine or chlorine provided that at least one of X3 and X4 is hydrogen; Y1 and Y2 are independently selected from hydrogen or alkyl; Z is = O or = S; R5, R6, R7 and R8 each independently hydrogen, -C F3, -COR10, alkyl or aryl, and further wherein R5 may be combined with R6 to represent = O or = S and / or R7 may be combined with R8 to represent = O or = S; R10, R19 and R20 independently represent hydrogen, alkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl and heterocycloalkylalkyl, provided that R19 and R20 are not both hydrogen; v is zero, 1, 2, or 3; and W is zero or 1, pharmaceutical compositions that are inhibitors of the enzyme, farnesyl protein transferase and use of said compounds to prepare useful drugs to inhibit abnormal cell growth.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87704997A | 1997-06-17 | 1997-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013094A1 true AR013094A1 (en) | 2000-12-13 |
Family
ID=25369144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102858A AR013094A1 (en) | 1997-06-17 | 1998-06-16 | N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0989979A1 (en) |
| JP (1) | JP2002506444A (en) |
| KR (1) | KR20010013881A (en) |
| CN (1) | CN1267291A (en) |
| AR (1) | AR013094A1 (en) |
| AU (1) | AU8253598A (en) |
| CA (1) | CA2293706C (en) |
| CO (1) | CO4940458A1 (en) |
| HU (1) | HUP0002954A3 (en) |
| IL (1) | IL133389A0 (en) |
| NZ (1) | NZ501571A (en) |
| PE (1) | PE82799A1 (en) |
| WO (1) | WO1998057948A1 (en) |
| ZA (1) | ZA985205B (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| WO2002028381A2 (en) * | 2000-10-05 | 2002-04-11 | Daley George Q | Methods of inducing cancer cell death and tumor regression |
| WO2002028409A2 (en) * | 2000-10-05 | 2002-04-11 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| JP4769082B2 (en) * | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | Urea derivatives, their production and use |
| AU2014239542A1 (en) * | 2013-03-15 | 2015-10-01 | Araxes Pharma Llc | Covalent inhibitors of KRas G12C |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| JO3805B1 (en) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | Inhibitors of kras g12c |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| BR112017021869A2 (en) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | substituted quinazoline compounds and methods of use thereof |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| JP2018533939A (en) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Method for screening for inhibitors of RAS |
| MX2018005967A (en) | 2015-11-16 | 2018-08-29 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof. |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (en) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Inhibitor of KRAS G12C mutant protein |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110831933A (en) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | Quinazoline derivatives as modulators of mutated KRAS, HRAS or NRAS |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| JP2020521741A (en) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | Compounds for the treatment of cancer and methods of their use |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN111960990A (en) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | Auxiliary agent and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them |
| WO1997023478A1 (en) * | 1995-12-22 | 1997-07-03 | Schering Corporation | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL128951A0 (en) * | 1996-09-13 | 2000-02-17 | Schering Corp | Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| CN1122031C (en) * | 1996-09-13 | 2003-09-24 | 先灵公司 | Substituted benzoarylheptopyridine derivatives useful as farnesyl protein transferase inhibitors |
-
1998
- 1998-06-15 JP JP50450299A patent/JP2002506444A/en not_active Ceased
- 1998-06-15 PE PE1998000506A patent/PE82799A1/en not_active Application Discontinuation
- 1998-06-15 ZA ZA985205A patent/ZA985205B/en unknown
- 1998-06-15 AU AU82535/98A patent/AU8253598A/en not_active Abandoned
- 1998-06-15 IL IL13338998A patent/IL133389A0/en unknown
- 1998-06-15 NZ NZ501571A patent/NZ501571A/en unknown
- 1998-06-15 CA CA002293706A patent/CA2293706C/en not_active Expired - Fee Related
- 1998-06-15 HU HU0002954A patent/HUP0002954A3/en unknown
- 1998-06-15 WO PCT/US1998/011507 patent/WO1998057948A1/en not_active Ceased
- 1998-06-15 KR KR1019997011903A patent/KR20010013881A/en not_active Withdrawn
- 1998-06-15 CN CN98808189A patent/CN1267291A/en active Pending
- 1998-06-15 EP EP98932717A patent/EP0989979A1/en not_active Withdrawn
- 1998-06-16 AR ARP980102858A patent/AR013094A1/en unknown
- 1998-06-16 CO CO98034144A patent/CO4940458A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE82799A1 (en) | 1999-08-26 |
| CN1267291A (en) | 2000-09-20 |
| JP2002506444A (en) | 2002-02-26 |
| CA2293706A1 (en) | 1998-12-23 |
| WO1998057948A1 (en) | 1998-12-23 |
| HUP0002954A3 (en) | 2002-11-28 |
| CO4940458A1 (en) | 2000-07-24 |
| ZA985205B (en) | 1998-12-15 |
| CA2293706C (en) | 2008-11-18 |
| NZ501571A (en) | 2002-02-01 |
| EP0989979A1 (en) | 2000-04-05 |
| KR20010013881A (en) | 2001-02-26 |
| AU8253598A (en) | 1999-01-04 |
| IL133389A0 (en) | 2001-04-30 |
| HUP0002954A2 (en) | 2001-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013094A1 (en) | N-SUBSTITUTED UREA COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE OF SUCH COMPOUNDS TO PREPARE MEDICINES | |
| AR029216A1 (en) | NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE | |
| DK0650476T3 (en) | Peripheral vasodilating agent containing N-acylated 4-aminopiperidine derivatives as active ingredients | |
| TR199902203T2 (en) | 1,8-anele quinolinone derivatives substituted with fernesyl transferase inhibitor, N- or C-linked imidazoles. | |
| DK365184D0 (en) | 1,8-NAPHTHYRIDINE DERIVATIVES OR ESTERS OR SALTS THEREOF, THEIR PREPARATION AND USE AS PHARMACEUTICALS | |
| CO4650042A1 (en) | 6-PHENYLPIRIDYL-2-AMINE DERIVATIVES | |
| PE20011001A1 (en) | HETEROCYCLIC COMPOUNDS AS SODIUM / PROTON EXCHANGE INHIBITORS | |
| ES2195034T3 (en) | METALOPROTEINASE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING THIS INHIBITOR AND ITS PHARMACEUTICAL USE, AND PROCEDURES THAT SERVE FOR PREPARATION. | |
| ES2196772T3 (en) | AMINO CYCLES COMPOUNDS. | |
| AR025276A1 (en) | THE USE OF A COMPOUND THAT IS A DERIVATIVE OF 2-AMINO-1,3-TIAZOL, A COMPOUND THAT IS A DERIVATIVE OF 2-AMINO-1,3-TIAZOL, A PROCEDURE TO PRODUCE IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| CO5570660A2 (en) | MODIFIED C-6 INDAZOLILPIRROLOTRIAZINAS | |
| ES2196806T3 (en) | DERIVATIVES OF FENILUREA AND FENILTIOUREA. | |
| ES2150577T3 (en) | AROMATIC AMINOETERES AS AGENTS TO RELIEF PAIN. | |
| DK0928788T3 (en) | Imidazolidin-4-one derivatives useful as anticancer agents | |
| FR2599740B1 (en) | BENZO (B) THIOPHENE DERIVATIVES OF BENZO (B) FURANNECARBOXAMIDES, PROCESSES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | |
| AR020165A1 (en) | DERIVATIVES OF REPLACED PYRIMIDINS, ITS PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF THEM FOR THE PREPARATION OF MEDICINES | |
| BR9811557A (en) | Derivatives of 2-) 4-aryl or heteroaryl-piperazin-1-ylmethyl) -1h-indole | |
| DK39286D0 (en) | IMIDAZOLD DERIVATIVES, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES | |
| AR019674A1 (en) | ANTHROMBROTIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2094146T3 (en) | DERIVATIVES OF PIRIDAZINE, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| PE20040750A1 (en) | DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 | |
| ES2090024T3 (en) | CEFEMO COMPOUNDS AND PROCEDURES FOR ITS PREPARATION. | |
| AR041218A1 (en) | DERIVADOS DE INDOLILO, A PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF THE COMPOUND TO PREPARE A MEDICINAL PRODUCT | |
| AR027578A1 (en) | INDANO DERIVATIVES | |
| MX9603998A (en) | 5-ht3 receptor agonist, novel thiazole derivative, and intermediate therefor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |